Latest Commercialization News

Universal Biosensors reported a 44% increase in net loss to A$10.45 million for H1 2025, alongside an 11% revenue decline, raising serious going concern doubts. The company is pursuing an A$8.5 million senior secured loan and equity raise to sustain operations.

Race Oncology’s Phase 1b/2 trial of RC110 bisantrene for relapsed or refractory acute myeloid leukemia has demonstrated a 40% response rate, exceeding expectations and offering new hope for difficult-to-treat patients.

Hudson Investment Group faces intense scrutiny from ASX after its auditor issued a Disclaimer of Opinion on the 2024 financial report, citing doubts over a $2.4 million property receivable and the company’s going concern status.

The Lederer Group has made an unsolicited off-market takeover offer for Elanor Commercial Property Fund at 70 cents per security, prompting the Fund's board to carefully consider its response.

HeraMED advances AI-driven maternity care partnerships and strengthens its US commercial team, navigating policy uncertainties while progressing its global expansion and funding strategies.

HeraMED Limited has raised $1.98 million through a discounted share placement to fund its digital maternity care platform's commercial growth across the US, Australia, and Europe.

Chilwa Minerals has raised A$4.1 million through a private placement to fast-track exploration and development at its multi-commodity Chilwa Project in Malawi, with directors backing the raise subject to shareholder approval.

The Lederer Group has announced an off-market takeover offer for all stapled securities in the Elanor Commercial Property Fund at 70 cents each, representing a premium over recent trading prices. The bid comes amid governance concerns and a proposed overhaul of the fund’s management structure.

Papyrus Australia Ltd has announced a $262,000 capital raise through a share placement and unlisted options, aiming to strengthen its working capital and research efforts.

QPM Energy Limited has completed commissioning of its Townsville Power Station and initiated a pivotal Dispatch Agreement with Ratch Australia Corporation, setting the stage for enhanced electricity market participation.

Rhythm Biosciences has advanced its ColoSTAT® diagnostic kits to final production validation, demonstrating consistent detection of colorectal cancer across all stages in a pivotal study. The company is gearing up for regulatory submission and commercial launch later this year.

Medallion Metals has executed a binding agreement to acquire the Forrestania Nickel Operation from IGO Limited, setting the stage for a low-capital pathway to gold and copper production at its Ravensthorpe project. The transaction targets completion and a final investment decision by late 2025.